Literature DB >> 25032738

Extraction optimisation and isolation of triterpenoids from Ganoderma lucidum and their effect on human carcinoma cell growth.

Weimei Ruan1, Andrew Hiang He Lim, Lau Gek Huang, David G Popovich.   

Abstract

The response surface methodology was used to optimise the extraction conditions of Ganoderma lucidum based on a Box-Behnken design. A quadratic model sufficiently simulated the response of ganoderic acid H with a determination coefficient (R(2)) of 0.98. The optimal condition for extracting triterpenoids was determined to be 100.00% ethanol at 60.22°C for 6.00 h, under which the yield of the reference triterpenoid ganoderic acid H increased from 0.88 to 2.09 mg/g powder. Following extraction, triterpenoid-enriched fraction was further isolated into 23 fractions, and 7 fractions were identified as ganoderic acids A, B, D, G, H and I and ganoderenic acid D. Of the seven triterpenoids, ganoderenic acid D was most cytotoxic with IC50 values of 0.14 ± 0.01, 0.18 ± 0.02 and 0.26 ± 0.03 mg/mL in Hep G2, Hela and Caco-2 cells, respectively. While ganoderic acids A, G and H were relatively non-cytotoxic. The variation of inhibitory effects for these triterpenoids was likely related to their chemical structures.

Entities:  

Keywords:  Ganoderma lucidum; cytotoxicity; isolation; response surface methodology; triterpenoids

Mesh:

Substances:

Year:  2014        PMID: 25032738     DOI: 10.1080/14786419.2014.938337

Source DB:  PubMed          Journal:  Nat Prod Res        ISSN: 1478-6419            Impact factor:   2.861


  2 in total

1.  Optimization of ultrasonic-assisted extraction of polysaccharides and triterpenoids from the medicinal mushroom Ganoderma lucidum and evaluation of their in vitro antioxidant capacities.

Authors:  Shizhong Zheng; Weirui Zhang; Shengrong Liu
Journal:  PLoS One       Date:  2020-12-31       Impact factor: 3.240

2.  Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune®) in TRAMP Mice.

Authors:  Peihe Liang; Jia Guo; Shadan Li; Qiunong Guan; Terry Vanderheyden; Alan So; Yuzhuo Wang; Tao Chen; Caigan Du
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-14       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.